-: We take a digital-first approach,
challenging ourselves to create products, capabilities,
and insights that are positively disruptive
or raise the standard of care.
(lively music)
-: I'm delighted to welcome Lidia Fonseca,
Executive Vice President
and Chief Digital and Technology Officer
at Pfizer since 2019.
Lidia, welcome, and thank you for joining me.
Tell us about Pfizer's bold digital transformation
a little more.
-: First, we lead
with the experience we're trying to create
for patients, physicians, payers, regulators,
and our own colleagues.
Second, we take a digital-first approach,
challenging ourselves to create products, capabilities,
and insights that are positively disruptive
or raise the standard of care.
Third, we bring digital innovation
across our entire value chain horizontally
so that we can achieve maximum impact.
We're driving end-to-end innovation
with three strategic priorities in mind:
to improve patient health outcomes,
to bring medicines to patients faster,
and fuel tomorrow's breakthrough therapies,
starting with research and discovery,
where supercomputing capabilities
with AI and machine learning are helping our scientists
accelerate compounds through discovery to development.
We leverage virtual in silico screening,
which refers to sophisticated computational modeling
and simulation techniques
that test molecular compounds in a virtual lab.
This capability reduces computational times by 80 to 90%,
quickly narrowing down to only those compounds
with the highest chance of becoming the medicine we need.
-: How do we leverage digital data and AI
and how this program has accelerated your purpose
and what the biggest wins are so far?
-: We're also using generative AI modeling
to design entirely new molecules with optimal activity,
searching beyond known molecules
to propose entirely new chemical structures.
In clinical development,
digital brings the trial to the participant
through remote trials,
helping boost recruitment, retention, and diversity
while elevating the participant experience.
AI and machine learning are enabling our teams
to perform quality checks
and analyze vast amounts of clinical trial data
50% faster than prior methods.
Over on the manufacturing front,
our patent-pending Digital Operations Center
provides an end-to-end view of manufacturing and supply.
This allows the team to predict issues
and adjust in real time
and has yielded 20% increase in throughput.